Gsk (GLAXF) Receivables - Other (2016 - 2025)
Gsk has reported Receivables - Other over the past 10 years, most recently at $1.5 billion for Q4 2025.
- Quarterly results put Receivables - Other at $1.5 billion for Q4 2025, up 38.7% from a year ago — trailing twelve months through Dec 2025 was $1.5 billion (up 38.7% YoY), and the annual figure for FY2025 was $1.5 billion, up 38.7%.
- Receivables - Other for Q4 2025 was $1.5 billion at Gsk, up from $1.1 billion in the prior quarter.
- Over the last five years, Receivables - Other for GLAXF hit a ceiling of $1.7 billion in Q4 2021 and a floor of $1.1 billion in Q4 2024.
- Median Receivables - Other over the past 5 years was $1.4 billion (2022), compared with a mean of $1.4 billion.
- Biggest five-year swings in Receivables - Other: decreased 15.74% in 2022 and later soared 38.7% in 2025.
- Gsk's Receivables - Other stood at $1.7 billion in 2021, then decreased by 15.74% to $1.4 billion in 2022, then decreased by 9.81% to $1.3 billion in 2023, then decreased by 15.19% to $1.1 billion in 2024, then soared by 38.7% to $1.5 billion in 2025.
- The last three reported values for Receivables - Other were $1.5 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.3 billion (Q4 2023) per Business Quant data.